Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Effect of 30mcg and Levonorgestrel 150 Combined Oral Contraceptive, Etonogestrel-releasing Subdermal Implant and Levonorgestrel-releasing Intrauterine System on Breast-Milk Production and Infant Growth in Fully Breast-Feeding Women
Brief Summary: The investigators propose a randomized clinical trial comparing the effect of 30 mcg ethinyl estradiol and LNG 150 combination oral contraceptive pills versus placebo, or LNG-IUS or Etonogestrel-releasing contraceptive implant (Implanon)on breast-milk intake and infant growth in exclusively breastfeeding mother-infant pairs. Mother-infant pairs will be randomly assigned either 30 microgram ethinyl estradiol combination oral contraceptive pills or identical placebo to start on post-partum day number 42 or Implanon implants or a LNG-IUS. All women will be offered nonhormonal contraceptives prior to randomization. The pairs will then be followed for four weeks. During this follow-up period, breast-milk intake will be quantified by administering deuterium oxide to exclusively breast-feeding mothers and measuring the enrichment of deuterium oxide in the saliva of their infants, otherwise known as the dose-to-mother method of Coward.17 Additionally, maternal and infant anthropometric measurements will be collected -- both as a value necessary to implement the breast-milk quantification method, as well as an outcome for analysis, and a daily diary will be kept by the women participating in the study that records infant feeds and diaper changes.


Options:
A: Inclusion Criteria:

* women at the day 42th of post-partum fully breastfeeding-

Exclusion Criteria:

* baby premature
* diabetes
* blood hypertension
* not breastfeeding or partial breastfeeding
B: Inclusion Criteria: Patients on the postpartum ward at University Hospital will be offered inclusion in the study if they are:

* healthy,
* 18-40 years old,
* delivered a healthy term infant,
* intend to breastfeed,
* desire Implanon as their method of contraception, and
* agree to be randomized to early versus standard postpartum insertion.

Exclusion Criteria:

* obstetric complications including anemia with hematocrit\<30,
* transfusion,
* infection,
* severe pregnancy induced hypertension,
* prolonged hospitalization,
* coagulopathy,
* liver disease,
* undiagnosed genital bleeding,
* or other relative contraindication to Implanon® insertion (known or suspected pregnancy, known, suspected, or history of breast cancer, or hypersensitivity to any of the components in Implanon®).
* Women taking drugs that are potent inducers of hepatic enzymes will also be excluded, including barbiturates, griseofulvin, rifampin, phenylbutazone, phenytoin, carbamazepine, felbamate, oxcarbazepine, topiramate, modafinil, protease inhibitors, and herbal products including St. John's Wort.
C: Inclusion Criteria:

* able to give informed consent
* postpartum women delivering at the University of New Mexico Hospital
* Intend to breastfeed
* Plan to use oral contraceptives as her family planning method
* Willing to be randomized to either progestin-only pills or combined pills

Exclusion Criteria:

* medical contraindications to combined pills including history of thromboembolism, uncontrolled hypertension or complex migraine headaches
* preterm birth (\<37 weeks)
* small for gestational age infant (\<2500 grams)
* large for gestational age infant (\>4500 grams)
* infant with major congenital anomaly
D: Inclusion Criteria:

* age between 18 and 35 years
* Postpartum contraception desire

Exclusion Criteria:

* smoking, alcoholism or drug addiction
* presence of systemic diseases (diabetis melittus, cardiovascular disease, autoimmune diseases, liver disease, thyroid disease, or congenital renal hyperplasia)
* having a body mass index ≥ 30 kg/m2
* personal history of arterial or venous thrombosis
* using any medication that might interfere with blood coagulation or with the assessment of haemostatic and inflammatory variables
* presenting alterations in hepatic enzymes
* being allergic to local anaesthetics (xylocaine)

Answer: A